Abstract
In 2003 Duke University (Durham, NC, USA) launched the Institute for Genome Sciences & Policy (IGSP) as an interdisciplinary network of centers comprised of scientists, engineers and physicians, as well as experts in law, business, economics public policy and ethics. Within this environment, the IGSP and its Center for Genomic Medicine form the hub for pharmacogenomic research discovery initiatives through collaborations with other scientific and clinical units at the Duke University Medical Center. The Center for Genomic Medicine specifically focuses on developing strategies for translating and implementing pharmacogenomic discoveries into the clinical arena; therefore, by harnessing the resources of the IGSP as well as other complementary centers on campus, Duke University is poised to accelerate the development of novel pharmacgenomic paradigms for the prevention and treatment of disease. These new treatment paradigms can, potentially, ensure that the right dose of the right drug is prescribed to the right individual - an often stated goal of personalized medicine and pharmacogenomics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
